Journal article
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
Abstract
We have analyzed the relationship between dose intensity of cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant chemotherapy of stage II breast cancer and 3-year relapse-free survival. Studies using only one or two drugs of CMF or melphalan instead of cyclophosphamide were included in the analysis by using simple techniques developed for this purpose. There was a clear-cut relationship between relapse-free survival and …
Authors
Hryniuk W; Levine MN
Journal
Journal of Clinical Oncology, Vol. 4, No. 8, pp. 1162–1170
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
August 1986
DOI
10.1200/jco.1986.4.8.1162
ISSN
0732-183X
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials as TopicCyclophosphamideDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorouracilHumansLymph NodesMenopauseMethotrexateMiddle AgedNeoplasm StagingPrednisonePrognosisRandom AllocationStatistics as TopicVincristine